5

10

15

20

25

What is claimed is:

1. A composition of matter of the formula

$$P^{1}-(L^{1})_{3}-F^{1}$$

and multimers thereof, wherein:

F¹ is a vehicle and is attached at the C-terminus of P¹-(L¹)_a;

P¹ is a PTH/PTHrP modulating domain;

L1 is a linker; and

a is 0 or 1.

2. The composition of matter of Claim 1 of the formulae P^1-F^1 .

3. The composition of matter of Claim 1, wherein F¹ is an Fc domain.

4. The composition of matter of Claim 1 wherein F¹ is an IgG Fc domain.

5. The composition of matter of Claim 1 wherein F¹ is an IgG1 Fc domain.

- 6. The composition of matter of Claim 1 wherein F¹ comprises the sequence of SEQ ID NO: 2.
- 7. The composition of matter of Claim 1 wherein the PTH/PTHrP modulating domain is of the formula

 $X^{N}HX^{10}X^{11}X^{12}KX^{14}X^{15}X^{16}X^{17}X^{18}X^{19}RX^{21}X^{22}X^{23}X^{24}X^{25}X^{26}X^{27}X^{28}X^{C}$

(SEQ ID NO: 3)

wherein:

 X^{N} is absent or is $X^{3}X^{4}X^{5}X^{6}X^{7}$, $X^{2}X^{3}X^{4}X^{5}X^{6}X^{7}$, $X^{1}X^{2}X^{3}X^{4}X^{5}X^{6}X^{7}$, or $YX^{1}X^{2}X^{3}X^{4}X^{5}X^{6}X^{7}$:

- X^1 through X^7 , X^{10} , X^{11} , X^{12} , X^{14} through X^{28} are each independently amino acid residues;
 - X^{c} is absent or is X^{29} , $X^{29}X^{30}$, $X^{29}X^{30}X^{31}$, $X^{29}X^{30}X^{31}X^{32}$, $X^{29}X^{30}X^{31}X^{32}X^{33}$, $X^{29}X^{30}X^{31}X^{32}X^{33}$, $X^{29}X^{30}X^{31}X^{32}X^{33}X^{34}X^{35}$, or $X^{29}X^{30}X^{31}X^{32}X^{33}X^{34}X^{35}$;

 X^{29} through X^{36} are each independently amino acid residues.

8. The composition of matter of Claim 7, wherein:

 X^{N} is $X^{1}X^{2}X^{3}X^{4}X^{5}X^{6}X^{7}$;

X¹ is a hydrophilic or nonfunctional residue;

5 X^2 is V;

 X^3 is S;

 X^4 is E;

X⁵ is a nonfunctional or basic residue;

 X^6 is Q;

 X^7 is L:

X¹⁰ is an acidic or hydrophilic residue;

X¹¹ is a nonfunctional or basic residue;

X¹² is a nonfunctional residue;

X¹⁴ is a basic or hydrophilic residue;

15 X^{15} is a nonfunctional residue;

X¹⁶ is a nonfunctional or hydrophilic residue;

X¹⁷ is an acidic, hydrophilic, or nonfunctional residue;

X¹⁸ is a nonfunctional residue;

X¹⁹ is an acidic or basic residue;

 X^{21} is a nonfunctional or basic residue;

X²² is a hydrophilic, acidic, or aromatic residue;

X²³ is an aromatic or lipophilic residue;

X²⁴ is a lipophilic residue (L preferred);

-X²⁵ is a hydrophilic or basic residue;

 X^{26} is a hydrophilic or basic residue;

X²⁷ is a lipophilic, basic, or nonfunctional residue; and

 X^{28} is a lipophilic or nonfunctional residue.

9. The composition of matter of Claim 8, wherein:

 X^{C} is $X^{29}X^{30}X^{31}X^{32}X^{33}X^{34}$;

10

15

```
X<sup>29</sup> is a hydrophilic or nonfunctional residue;
```

X³⁰ is a hydrophilic or acidic residue;

X³¹ is a lipophilic or nonfunctional residue;

 X^{32} is H;

X³³ is a hydrophilic residue; and

X³⁴ is a nonfunctional or aromatic residue.

10. The composition of matter of Claim 8, wherein:

 X^{C} is $X^{29}X^{30}X^{31}$;

X²⁹ is a hydrophilic or nonfunctional residue;

X³⁰ is a hydrophilic or acidic residue; and

 X^{31} is a lipophilic or nonfunctional residue.

11. The composition of matter of Claim 8, wherein:

 X^{c} is $X^{29}X^{30}$;

 X^{29} is a hydrophilic or nonfunctional residue; and

 X^{30} is a hydrophilic or acidic residue.

12. The composition of matter of Claim 8, wherein:

 X^{c} is X^{29} ; and

 X^{29} is a hydrophilic or nonfunctional residue.

- 13. The composition of matter of Claim 8, wherein X^{c} is absent.
- 20 14. The composition of matter of Claim 8, wherein:

 X^1 is A, S or Y;

 X^5 is H or I;

 X^{10} is N or D;

 X^{11} is L, R, or K;

25 X^{12} is G, F, or W;

 X^{14} is H or S;

 X^{15} is L or I;

 X^{16} is Q, N, S, or A;

 X^{17} is S, D, or L;

```
A-665B
```

```
X<sup>18</sup> is M, L, V or Nle;
                                     X^{19} is E or R;
                                     X^{21} is V, M, R, or Nle;
                                     X^{22} is E or F;
                                     X^{23} is W or F;
             5
                                     X^{25} is R or H;
                                     X<sup>26</sup> is K or H;
                                     X<sup>27</sup> is K or L; and
                                     X^{28} is L or I.
COOLUNE FEET FORD
                            The composition of matter of Claim 14, wherein:
            10
                   15.
                                     X^{C} is X^{29}X^{30}X^{31}X^{32}X^{33}X^{34};
                                     X^{29} is O or A:
                                     X^{30} is D or E;
                                     X^{31} is V or I:
                                     X^{33} is N or T; and
            15
                                     X^{34} is A, F or Y.
                   16.
                            The composition of matter of Claim 14, wherein:
                                     X^{C} is X^{29}X^{30}X^{31};
                                     X^{29} is Q or A;
                                     X<sup>30</sup> is D or E; and
            20
                                     X^{31} is V or I:
                            The composition of matter of Claim 14, wherein:
                   17.
                                     X^{C} is X^{29}X^{30};
                                     -X^{29} is Q-or-A; and
                                     X^{30} is D or E.
            25
                            The composition of matter of Claim 14, wherein:
                   18.
                                     X^{c} is X^{29}; and
```

 X^{29} is Q or A.

19.

The composition of matter of Claim 14, wherein X^{c} is absent.

20. The composition of matter of Claim 1, wherein the PTH/PTHrP modulating domain is of the formula

> $J^{N}J^{7}J^{8}HNJ^{11}J^{12}KHLJ^{16}SJ^{18}J^{19}RJ^{21}EWLRKKLJ^{C} \\$ (SEO ID NO: 4)

		(SEQ ID NO: 4)
	5	wherein:
qui qui dun i'u das Enl das		J^N is absent or is selected from $J^1J^2J^3J^4J^5J^6$, $J^2J^3J^4J^5J^6$, $J^3J^4J^5J^6$;
		J¹ is an amino acid residue;
		J² is an amino acid residue;
		J³ is an amino acid residue;
	10	J⁴ is an amino acid residue;
		J^{5} is an amino acid residue;
U		J^{6} is an amino acid residue;
i.i.		J^{7} is an amino acid residue;
		J [®] is an amino acid residue;
	15	J ¹¹ is a nonfunctional or basic residue;
ij		J^{12} is an amino acid residue;
`.⊒ .≟		J ¹⁶ is an amino acid residue;
		J ¹⁸ is an amino acid residue;
		J ¹⁹ is an acidic or basic residue;
	20	J ²¹ is an amino acid residue;
		J^{C} is absent or is J^{29} , $J^{29}J^{30}$, $J^{29}J^{30}J^{31}$, $J^{29}J^{30}J^{31}J^{32}$, $J^{29}J^{30}J^{31}J^{32}$,
		$J^{29}J^{30}J^{31}J^{32}J^{33}J^{34}$; and
		J ²⁹ is an amino acid residue;
		J [∞] is-an-amino-acid-residue;
	25	J^{31} is an amino acid residue;
		J³² is an amino acid residue;
		J ³³ is an amino acid residue;
		J ³⁴ is an amino acid residue.

		J^{N} is $J^{1}J^{2}J^{3}J^{4}J^{5}J^{6}$;
		J¹ is a nonfunctional or aromatic residue;
		J^2 is a nonfunctional residue;
		J³ is a hydrophilic residue;
	5	J ⁴ is an acidic residue;
		J^{5} is a nonfunctional residue;
		J ⁶ is a basic residue;
		J^{7} is a nonfunctional or aromatic residue;
		J ⁸ is a nonfunctional residue;
	10	J ¹¹ is a basic or a nonfunctional residue;
Ę		J ¹² is a nonfunctional or aromatic residue;
lu IU		J ¹⁶ is a nonfunctional or hydrophilic residue;
iu L		J ¹⁸ is a nonfunctional residue;
11 . 1		J ¹⁹ is an acidic or basic residue; and
	15	J^{21} is a nonfunctional residue;
i u i <u>n</u>		J^{c} is $J^{29}J^{30}J^{31}J^{32}J^{33}J^{34}$;
		J ²⁹ is a hydrophilic or nonfunctional residue;
		J^{30} is a hydrophilic or acidic residue;
		J ³¹ is a lipophilic or nonfunctional residue;
	20	J³² is a basic residue;
		J ³³ is an acidic residue; and
		J³⁴ is an aromatic residue.
		22. The composition of matter of Claim 21, wherein:
		J ¹ is-A, S-or-Y;
	25	J^2 is V ;
		J³ is S;
		J⁴ is E;
		J ⁵ is I;

J⁶ is Q;

```
J^7 is L or F;
                            J<sup>8</sup> is M or Nle;
                            J<sup>11</sup> is L, R, or K;
                            J<sup>12</sup> is G or W;
                            J<sup>16</sup> is N, S, or A;
 5
                            J<sup>18</sup> is M, Nle, L, or V;
                            J<sup>19</sup> is E or R;
                            J<sup>21</sup> is V, M, or Nle;
                            J<sup>29</sup> is Q or A;
                            I<sup>30</sup> is D or E;
10
                            I<sup>31</sup> is V or I;
                            I^{32} is H;
                            J<sup>33</sup> is N; and
                            J<sup>34</sup> is F or Y.
                  The composition of matter of Claim 20, wherein:
        23.
15
                            I^{N} is I^{1}I^{2}I^{3}I^{4}I^{5}I^{6};
                            J<sup>1</sup> is a nonfunctional or aromatic residue;
                            J<sup>2</sup> is a nonfunctional residue;
                            J<sup>3</sup> is a hydrophilic residue;
                            J<sup>4</sup> is an acidic residue;
20
                            J⁵ is a nonfunctional residue;
                            J<sup>6</sup> is a basic residue;
                            J<sup>7</sup> is a nonfunctional or aromatic residue;
                            -J<sup>®</sup>is-a-nonfunctional-residue;-
                            J<sup>11</sup> is a basic or a nonfunctional residue;
25
                            J<sup>12</sup> is a nonfunctional or aromatic residue;
                            J<sup>16</sup> is a nonfunctional or hydrophilic residue;
                            J<sup>18</sup> is a nonfunctional residue;
                            J<sup>19</sup> is an acidic or basic residue;
```

```
A-665B
```

```
J<sup>21</sup> is a nonfunctional residue;
                            J^{c} is J^{29}J^{30}J^{31};
                            J<sup>29</sup> is a hydrophilic or nonfunctional residue;
                            J<sup>30</sup> is a hydrophilic or acidic residue; and
                            J<sup>31</sup> is a lipophilic or nonfunctional residue.
 5
                  The composition of matter of Claim 23, wherein:
        24.
                            J<sup>1</sup> is A, S or Y;
                            J<sup>2</sup> is V;
                           J^3 is S;
                            J⁴ is E;
10
                           J<sup>5</sup> is I;
                           J<sup>6</sup> is Q;
                           J^7 is L or F;
                           J<sup>8</sup> is M or Nle;
                           J<sup>11</sup> is L, R, or K;
15
                           J<sup>12</sup> is G or W;
                           J<sup>16</sup> is N, S, or A;
                           J<sup>18</sup> is M, Nle, L, or V;
                           I<sup>19</sup> is E or R;
                           J^{21} is V, M, or Nle;
20
                           J^{29} is Q or A;
                           I<sup>30</sup> is D or E; and
                           J^{31} is V or I.
                 -The-composition-of-matter-of-Claim-20, wherein:
       25.
                           J^{N} is J^{1}J^{2}J^{3}J^{4}J^{5}J^{6};
25
                           J<sup>1</sup> is a nonfunctional or aromatic residue;
                           J<sup>2</sup> is a nonfunctional residue;
                           J<sup>3</sup> is a hydrophilic residue;
                           J⁴ is an acidic residue;
```

```
I⁵ is a nonfunctional residue;
                            J<sup>6</sup> is a basic residue;
                            J<sup>7</sup> is a nonfunctional or aromatic residue;
                            J<sup>8</sup> is a nonfunctional residue;
                            J<sup>11</sup> is a basic or a nonfunctional residue;
 5
                            J<sup>12</sup> is a nonfunctional or aromatic residue;
                            J<sup>16</sup> is a nonfunctional or hydrophilic residue;
                            J<sup>18</sup> is a nonfunctional residue;
                            J<sup>19</sup> is an acidic or basic residue;
                            J<sup>21</sup> is a nonfunctional residue;
10
                            I^{C} is I^{29}I^{30};
                            J<sup>29</sup> is a hydrophilic or nonfunctional residue; and
                            J<sup>30</sup> is a hydrophilic or acidic residue.
                  The composition of matter of Claim 25, wherein:
        26.
                            J<sup>1</sup> is A, S or Y;
15
                            J<sup>2</sup> is V;
                            J^3 is S;
                            J⁴ is E;
                            I<sup>5</sup> is I;
                           J<sup>6</sup> is Q;
20
                            J<sup>7</sup> is L or F;
                            J<sup>8</sup> is M or Nle;
                            J<sup>11</sup> is L, R, or K;
                           -J<sup>12</sup> is-G-or-W;---
                           J<sup>16</sup> is N, S, or A;
25
                           J<sup>18</sup> is M, Nle, L, or V;
                           J<sup>19</sup> is E or R;
                           J^{21} is V, M, or Nle;
                           J<sup>29</sup> is Q or A; and
```

```
J^{30} is D or E.
```

27. The composition of matter of Claim 20, wherein:

 J^{N} is $J^{1}J^{2}J^{3}J^{4}J^{5}J^{6}$;

J¹ is a nonfunctional or aromatic residue;

5 J² is a nonfunctional residue;

J³ is a hydrophilic residue;

J⁴ is an acidic residue;

J⁵ is a nonfunctional residue;

J⁶ is a basic residue;

I⁷ is a nonfunctional or aromatic residue;

J⁸ is a nonfunctional residue;

J¹¹ is a basic or a nonfunctional residue;

J¹² is a nonfunctional or aromatic residue;

J¹⁶ is a nonfunctional or hydrophilic residue;

I¹⁸ is a nonfunctional residue;

I¹⁹ is an acidic or basic residue;

J²¹ is a nonfunctional residue;

 J^{c} is J^{29} ; and

J²⁹ is a hydrophilic or nonfunctional residue.

20 28. The composition of matter of Claim 27, wherein:

J¹ is A, S or Y;

J² is V;

 J^3 is S;

-J⁴is-E;-

 J^5 is I;

I⁶ is O;

J⁷ is L or F;

J⁸ is M or Nle;

J¹¹ is L, R, or K;

```
J^{12} is G or W;
                          J<sup>16</sup> is N, S, or A;
                          J<sup>18</sup> is M, Nle, L, or V;
                          J<sup>19</sup> is E or R;
                          J<sup>21</sup> is V, M, or Nle; and
 5
                          J<sup>29</sup> is Q or A.
                 The composition of matter of Claim 20, wherein:
       29.
                          J^{N} is J^{1}J^{2}J^{3}J^{4}J^{5}J^{6};
                          J<sup>1</sup> is a nonfunctional or aromatic residue;
                          J<sup>2</sup> is a nonfunctional residue;
10
                          J<sup>3</sup> is a hydrophilic residue;
                          I⁴ is an acidic residue;
                          J⁵ is a nonfunctional residue;
                          J<sup>6</sup> is a basic residue;
                          J<sup>7</sup> is a nonfunctional or aromatic residue;
15
                          J<sup>8</sup> is a nonfunctional residue;
                          J<sup>11</sup> is a basic or a nonfunctional residue;
                          J<sup>12</sup> is a nonfunctional or aromatic residue;
                          J<sup>16</sup> is a nonfunctional or hydrophilic residue;
                          J<sup>18</sup> is a nonfunctional residue;
20
                          J<sup>19</sup> is an acidic or basic residue;
                          J<sup>21</sup> is a nonfunctional residue; and
                          I<sup>c</sup> is absent.
                -The-composition-of-matter-of-Claim-29, wherein:
       30.
                          J<sup>1</sup> is A, S or Y;
25
                          J<sup>2</sup> is V;
                          I^3 is S;
                          J⁴ is E;
                          J<sup>5</sup> is I;
```

```
J^6 is Q;
                                      J^7 is L or F;
                                      J<sup>8</sup> is M or Nle;
                                      I<sup>11</sup> is L, R, or K;
                                      J<sup>12</sup> is G or W;
              5
                                      J<sup>16</sup> is N, S, or A;
                                      J<sup>18</sup> is M, Nle, L, or V;
                                      J<sup>19</sup> is E or R; and
                                      J^{21} is V, M, or Nle.
The composition of matter of Claim 20, wherein the PTH/PTHrP
                   31.
             10
                             modulating domain is selected from Table 1.
                             The composition of matter of Claim 1 wherein the PTH/PTHrP
                   32.
                             modulating domain is of the formula
                                         O<sup>N</sup>LHO<sup>10</sup>O<sup>11</sup>O<sup>12</sup>KSIO<sup>16</sup>O<sup>17</sup>LRRRFO<sup>23</sup>LHHLIO<sup>C</sup>
                                                             (SEQ ID NO: 5)
            15
                             wherein:
                                      O^{N} is absent or is YO^{1}O^{2}O^{3}O^{4}O^{5}O^{6}O^{7}, O^{1}O^{2}O^{3}O^{4}O^{5}O^{6}O^{7},
                                           O^{2}O^{3}O^{4}O^{5}O^{6}O^{7}, O^{3}O^{4}O^{5}O^{6}O^{7}, O^{4}O^{5}O^{6}O^{7}, O^{5}O^{6}O^{7}, O^{6}O^{7}, or
                                           O^7:
                                      O¹ is an amino acid residue;
            20
                                      O<sup>2</sup> is an amino acid residue;
                                      O<sup>3</sup> is an amino acid residue;
                                      O4 is an amino acid residue;
                                      -O⁵-is-an-amino-acid-residue;
                                      O<sup>6</sup> is an amino acid residue;
            25
                                      O<sup>7</sup> is an amino acid residue;
                                      O<sup>10</sup> is an amino acid residue;
                                      O11 is an amino acid residue;
                                      O<sup>12</sup> is an amino acid residue;
```

			O¹6 is an amino acid residue;
			O ¹⁷ is an amino acid residue;
			O ²³ is an amino acid residue;
			O^{C} is absent or is O^{29} , $O^{29}O^{30}$, $O^{29}O^{30}O^{31}$, $O^{29}O^{30}O^{31}O^{32}$,
	5		$O^{29}O^{30}O^{31}O^{32}O^{33}$, $O^{29}O^{30}O^{31}O^{32}O^{33}O^{34}$, $O^{29}O^{30}O^{31}O^{32}O^{33}O^{34}$,
			or O ²⁹ O ³⁰ O ³¹ O ³² O ³³ O ³⁴ O ³⁵ O ³⁶ ; and
			O^{29} through O^{36} are each independently amino acid residues.
		33.	The composition of matter of Claim 27, wherein:
J			O^N is O^7 ;
	10		O ⁷ is a nonfunctional residue;
			O ¹⁰ is an acidic or hydrophilic residue;
ly ly			O ¹¹ is a basic or nonfunctional residue;
4			O ¹² is an aromatic or nonfunctional residue;
1:			O ¹⁵ is a hydrophilic or nonfunctional residue;
	15		O ¹⁶ is a hydrophilic residue;
i u			O ¹⁷ is an acidic or nonfunctional residue;
] 4			O ²³ is an aromatic residue; and
			O ^c is absent.
		34.	The composition of matter of Claim 23, wherein:
	20		O^{N} is $O^{1}O^{2}O^{3}O^{4}O^{5}O^{6}O^{7}$;
			O¹ is a nonfunctional amino acid residue;
			O ² is a nonfunctional amino acid residue;
			O³ is a hydrophilic amino acid residue;
			———O⁴-is-an-acidic-amino-acid-residue;
	25		O ⁵ is a basic or nonfunctional amino acid residue;

O¹⁰ is an acidic or hydrophilic residue; O11 is a basic or nonfunctional residue;

O⁶ is a hydrophilic amino acid residue;

O⁷ is a nonfunctional residue;

10

15

 ${
m O}^{12}$ is an aromatic or nonfunctional residue; ${
m O}^{15}$ is a hydrophilic or nonfunctional residue; ${
m O}^{16}$ is a hydrophilic residue; and ${
m O}^{17}$ is an acidic or nonfunctional residue; and

 O^{23} is an aromatic residue.

35. The composition of matter of Claim 34, wherein:

O¹ is A;
O² is V;
O³ is S;
O⁴ is E;
O⁵ is H or I;
O⁶ is Q;
O⁻ is L;
O¹¹ is N or D;
O¹¹ is K or L;

O is N of D,

O¹¹ is K or L;

O¹² is G, F, or W;

O¹⁵ is I or S;

O¹⁶ is Q or N;

O¹⁷ is D or L;

O²³ is F or W.

- 36. The composition of matter of Claim 27, wherein the PTH/PTHrP modulating domain is selected from Table 2.
- 37. The composition of matter of Claim 1, wherein the PTH/PTHrP modulating-domain-has-the-amino-acid-sequence-of-TIP39.
- 25 38. The composition of matter of Claim 1, comprising a sequence selected from Table 4.
 - 39. A composition of matter, which comprises a peptide selected from SEQ ID NOS: 17, 18, 19, and 69.
 - 40. A nucleic acid encoding a composition of matter of Claim 1.

- 41. A nucleic acid encoding a composition of matter of Claim 7.
- 42. A nucleic acid encoding a composition of matter of Claim 20.
- 43. A nucleic acid encoding a composition of matter of Claim 32.
- 44. A nucleic acid encoding a composition of matter of Claim 39.
- 5 45. An expression vector comprising the DNA of Claim 40.
 - 46. An expression vector comprising the DNA of Claim 41.
 - 47. An expression vector comprising the DNA of Claim 42.
 - 48. An expression vector comprising the DNA of Claim 43.
 - 49. An expression vector comprising the DNA of Claim 44.
- 10 50. A host cell comprising the expression vector of Claim 45.
 - 51. A host cell comprising the expression vector of Claim 46.
 - 52. A host cell comprising the expression vector of Claim 47.
 - 53. A host cell comprising the expression vector of Claim 48.
 - 54. A host cell comprising the expression vector of Claim 49.
- 15 55. The cell of Claim 50, wherein the cell is an <u>E. coli</u> cell.
 - 56. The cell of Claim 51, wherein the cell is an <u>E. coli</u> cell.
 - 57. The cell of Claim 52, wherein the cell is an <u>E. coli</u> cell.
 - 58. The cell of Claim 53, wherein the cell is an <u>E. coli</u> cell.
 - 59. A process for preparing an antagonist of the PTH/PTHrP receptor, which comprises:
 - a) selecting at least one peptide that binds to the receptor; and
 - b) preparing a pharmacologic agent comprising at least one Fc
 domain covalently linked to at least one amino acid sequence of
 the-selected-peptide-or-peptides.
- 25 60. The process of Claim 59, wherein the peptide is selected from the SEQ ID NOS: 3, 4, or 5.
 - 61. The process of Claim 59, wherein the peptide is selected in a process comprising screening of a phage display library, an <u>E. coli</u>



5

10

15

20

- display library, a ribosomal library, an RNA-peptide library, or a chemical peptide library.
- 62. The process of Claim 59, wherein the preparation of the pharmacologic agent is carried out by:
 - a) preparing a gene construct comprising a nucleic acid sequence encoding the selected peptide and a nucleic acid sequence encoding an Fc domain; and
 - b) expressing the gene construct.
- 63. The process of Claim 59, wherein the gene construct is expressed in an <u>E. coli</u> cell.
- 64. The process of Claim 59, wherein the selection of the peptide is carried out by a process comprising:
 - a) preparing a gene construct comprising a nucleic acid sequence encoding a first selected peptide and a nucleic acid sequence encoding an Fc domain;
 - b) conducting a polymerase chain reaction using the gene construct and mutagenic primers, wherein
 - i) a first mutagenic primer comprises a nucleic acid sequence complementary to a sequence at or near the 5' end of a coding strand of the gene construct, and
 - ii) a second mutagenic primer comprises a nucleic acid sequence complementary to the 3' end of the noncoding strand of the gene construct.
- A-method-of-treating-osteopenia,-which-comprises-administering-a PTH agonist and a bone resorption inhibitor, wherein the PTH agonist comprises a composition of matter of Claim 1.
 - 66. A method of treating osteopenia, which comprises administering a PTH agonist and a bone resorption inhibitor, wherein the PTH agonist comprises a composition of matter of Claim 7.



5

15

- 67. A method of treating osteopenia, which comprises administering a PTH agonist and a bone resorption inhibitor, wherein the PTH agonist comprises a composition of matter of Claim 20.
- 68. A method of treating osteopenia, which comprises administering a PTH agonist and a bone resorption inhibitor, wherein the PTH agonist comprises a composition of matter of Claim 32.
 - 69. A method of treating osteopenia, which comprises administering a PTH agonist and a bone resorption inhibitor, wherein the PTH agonist comprises a composition of matter of Claim 39.
- The method of Claim 65, wherein the bone resorption inhibitor is selected from OPG, OPG-L antibody, calcitonin, bisphosphonates, estrogens, estrogen receptor modulators, and tibolone.
 - 71. The method of Claim 66, wherein the bone resorption inhibitor is selected from OPG, OPG-L antibody, calcitonin, bisphosphonates, estrogens, estrogen receptor modulators, and tibolone.
 - 72. The method of Claim 67, wherein the bone resorption inhibitor is selected from OPG, OPG-L antibody, calcitonin, bisphosphonates, estrogens, estrogen receptor modulators, and tibolone.
- 73. The method of Claim 68, wherein the bone resorption inhibitor is selected from OPG, OPG-L antibody, calcitonin, bisphosphonates, estrogens, estrogen receptor modulators, and tibolone.
 - 74. The method of Claim 69, wherein the bone resorption inhibitor is selected from OPG, OPG-L antibody, calcitonin, bisphosphonates, estrogens, estrogen-receptor-modulators, and-tibolone.
- 25 75. A method of treating osteopenia, which comprises administering a composition of matter of Claim 1.
 - 76. A method of treating osteopenia, which comprises administering a composition of matter of Claim 7.

- 77. A method of treating osteopenia, which comprises administering a composition of matter of Claim 20.
- 78. A method of treating osteopenia, which comprises administering a composition of matter of Claim 32.
- 5 79. A method of treating osteopenia, which comprises administering a composition of matter of Claim 39.